Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.
Study Goal
The researchers aimed to compare the benefits and harms of iron supplementation alone and as an adjunct to erythropoiesis-stimulating agents (ESAs) versus ESA alone in treating chemotherapy-induced anemia.
Results Summary
The study found that adding iron to ESAs improves hematopoietic response, reduces the need for red blood cell transfusions, and increases hemoglobin levels, with parenteral iron showing superiority over oral iron. The treatment was well tolerated.
Population
Patients with chemotherapy-induced anemia.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
iron supplementation alone | neutral | chemotherapy-induced anemia | - | - | benefits and harms | #1 |
iron as an adjunct to erythropoiesis-stimulating agents (ESAs) | neutral | chemotherapy-induced anemia | - | - | benefits and harms | #2 |
Addition of iron to ESAs | increase | hematopoietic response | - | - | improves | #3 |
Addition of iron to ESAs | decrease | the need for red blood cell transfusions | - | - | reduces | #4 |
Addition of iron to ESAs | increase | hemoglobin levels | - | - | increases | #5 |
Addition of iron to ESAs | no change | - | - | - | seems to be well tolerated | #6 |
parenteral iron | increase | treatment of chemotherapy-induced anemia | - | - | superiority | #7 |
oral iron supplementation | increase | treatment of chemotherapy-induced anemia | - | - | superiority | #8 |
CLINICAL QUESTION: What are the benefits and harms of iron supplementation alone and as an adjunct to erythropoiesis-stimulating agents (ESAs) compared with ESA alone in the treatment of chemotherapy-induced anemia? BOTTOM LINE: Addition of iron to ESAs improves hematopoietic response, reduces the need for red blood cell transfusions, increases hemoglobin levels, and seems to be well tolerated. The subgroup analyses suggest the superiority of parenteral iron over oral iron supplementation in the treatment of chemotherapy-induced anemia.